The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major ...

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Shares declined 3.2% in premarket trading. Peer stocks traded mixed. Johnson & Johnson was flat while Bristol Myers Squibb, ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

The 36-year-old Officer Didarul Islam was among those killed. The shooter’s motive is not yet clear. Here’s the latest.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...